Why the study?
Sirtuin 6 is understood to play a pivotal role in adipose tissue inflammation, with protein levels reduced in obese humans and animals.
Sirt6 plays a pivotal role in preventing adipose tissue inflammation and insulin resistance by regulating adipocytes, macrophages, and eosinophils, highlighting its potential as a therapeutic target for metabolic diseases.
Answers are grounded in this paper and cite their sources.
Sirt6 reduction may promote adipose inflammation in obesity; leaves open its therapeutic modulation pending interventional studies.
Adipose tissue (AT) inflammation is strongly associated with obesity-induced insulin resistance. When subjected to metabolic stress, adipocytes become inflamed and secrete a plethora of cytokines and chemokines, which recruit circulating immune cells to AT. Although sirtuin 6 (Sirt6) is known to control genomic stabilization, aging, and cellular metabolism, it is now understood to also play a pivotal role in the regulation of AT inflammation. Sirt6 protein levels are reduced in the AT of obese humans and animals and increased by weight loss. In this review, we summarize the potential mechanism of AT inflammation caused by impaired action of Sirt6 from the immune cells' point of view. We first describe the properties and functions of immune cells in obese AT, with an emphasis on discrete macrophage subpopulations which are central to AT inflammation. We then highlight data that links Sirt6 to functional phenotypes of AT inflammation. Importantly, we discuss in detail the effects of Sirt6 deficiency in adipocytes, macrophages, and eosinophils on insulin resistance or AT browning. In our closing perspectives, we discuss emerging issues in this field that require further investigation.
No takes yet. Share an insight, caveat, or question.
Bae et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: